Stock market today: S&P 500 extends monthly win streak despite Nvidia-led stumble
LONDON - N4 Pharma plc (AIM:N4P), a UK biotech developing the Nuvec gene delivery system, announced Tuesday the appointment of Edward Wardle as a non-executive director, effective immediately.
Wardle joins as a representative of Northern Standard Limited, the company’s largest shareholder. Northern Standard holds 150,000,000 ordinary shares in N4 Pharma, and Wardle personally holds 18,750,000 warrants exercisable at 0.4p per share, expiring April 4, 2030.
The 34-year-old brings experience in strategy, corporate governance and business development to the board. He currently serves as an investment adviser with Tracarta Limited and Northern Standard Limited, focusing on critical industries and technologies, while also working as a Senior Business Development Executive at Ironveld plc.
In May 2025, Wardle joined the board of AIM-listed TheraCryf plc, a clinical stage drug development company specializing in neuropsychiatry and oncology, as a non-executive director.
Nigel Theobald, Chief Executive Officer of N4 Pharma, stated that Wardle’s experience would be "invaluable as N4 Pharma develops its Nuvec platform and continues to build out its data packages to secure licensing opportunities."
Northern Standard Limited is 51% owned by Tracarta Limited, a company in which John Wardle, Edward’s father, has a beneficial interest. Edward Wardle owns 49% of Northern Standard Limited.
The company disclosed that The Dream Corporation Limited, where Wardle serves as a director, is currently undergoing creditors’ voluntary liquidation, with insolvency practitioners appointed in July 2024.
This information is based on a press release statement issued by N4 Pharma.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.